Pulmonx (LUNG) Cash from Financing Activities (2019 - 2025)
Pulmonx's (LUNG) quarterly Cash from Financing Activities came in at $181000.0 in Q3 2025, down 60.57% year-over-year from $459000.0 in Q3 2024, and up 370.15% quarter-over-quarter from -$67000.0 in Q2 2025.
Powered by 
Analysis
Pulmonx (LUNG) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Pulmonx (LUNG) has reported Cash from Financing Activities for 7 consecutive years, with $181000.0 the latest figure, recorded in Q3 2025.
- On a quarterly basis, Cash from Financing Activities fell 60.57% year-over-year to $181000.0 in Q3 2025; TTM through Sep 2025 was $840000.0, a 36.27% decrease from a year earlier, with the FY2024 full-year figure at $1.4 million, down 93.63% from the prior year.
- Cash from Financing Activities was $181000.0 for Q3 2025 at Pulmonx, up from -$67000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $20.7 million in Q1 2023 and troughed at -$67000.0 in Q2 2025.
- A 5-year average of $1.6 million and a median of $181000.0 in 2025 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities soared 10015.38% in 2022 and tumbled 204.55% in 2025, its largest moves.
- Over 5 years, Cash from Financing Activities stood at $150000.0 in 2021, then tumbled by 55.33% to $67000.0 in 2022, then slumped by 74.63% to $17000.0 in 2023, then surged by 264.71% to $62000.0 in 2024, then jumped by 191.94% to $181000.0 in 2025.
- The last three Cash from Financing Activities figures came in at $181000.0 (Q3 2025), -$67000.0 (Q2 2025), and $664000.0 (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | -287.90 Mn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | -343.00 Mn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | -95.00 Mn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | -410.00 Mn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | -300,000.00 |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | -510.00 Mn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | -607.30 Mn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Pulmonx | 75.94 Mn | 6.19 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 181,000.00 |
| Jun 30, 2025 | -67,000.00 |
| Mar 31, 2025 | 664,000.00 |
| Dec 31, 2024 | 62,000.00 |
| Sep 30, 2024 | 459,000.00 |
| Jun 30, 2024 | -22,000.00 |
| Mar 31, 2024 | 864,000.00 |
| Dec 31, 2023 | 17,000.00 |
| Sep 30, 2023 | 571,000.00 |
| Jun 30, 2023 | 92,000.00 |
| Mar 31, 2023 | 20.72 Mn |
| Dec 31, 2022 | 67,000.00 |
| Sep 30, 2022 | 906,000.00 |
| Jun 30, 2022 | 131,000.00 |
| Mar 31, 2022 | 1.32 Mn |
| Dec 31, 2021 | 150,000.00 |
| Sep 30, 2021 | 1.00 Mn |
| Jun 30, 2021 | 3.29 Mn |
| Mar 31, 2021 | 13,000.00 |
| Dec 31, 2020 | 199.77 Mn |